chao fang

Dr. chao fang

third xiangya hospital, central south university

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2017 in Scientific Reports
Verified
Journal Article
Open access
CFchao fang
chao fang
YCYi-Xin Chen
Yi-Xin Chen
NWNa-Yi Yuan Wu
Na-Yi Yuan Wu
JYJiye Yin
Jiye Yin
XLXiang-Ping Li
Xiang-Ping Li
ZLZhao-Qian Liu
Zhao-Qian Liu
Our previous studied indicated that eukaryotic translation initiation factor 3a (eIF3a) increases the sensitive of platinum-based chemotherapy in lung cancer. MiRNAs play an important role in lung carcinogenesis and drug response. In this study, we aimed to identify potential endogenous miRNAs that inhibit eIF3a expression and determine their influence of this inhibition on cisplatin resistance. Using bioinformatics analysis prediction and confirmation with dual-luciferase reporter assays, we found that miRNA-488 inhibited eIF3a expression by directly binding to the 3’UTR of eIF3a. In addition, the overexpression of miRNA-488 inhibited cell migration and invasion in A549 cells, and also inhibited cell proliferation, cell cycle progression by elevated P27 expression. Compared to the parental cell line, A549/cisplatin (DDP) resistant cells exhibited a higher level of miRNA-488. Moreover, we found that miRNA-488 was associated with cisplatin resistance in three NSCLC cells (A549, H1299 and SK-MES-1). The mechanism of miRNA-488 induced cisplatin resistance was that miRNA-488 activated nucleotide excision repair (NER) by increasing the expression of Replication Protein A (RPA) 14 and Xeroderma pigmentosum group C (XPC). In conclusion, our results demonstrated that miRNA-488 is a tumor suppressor miRNA that acts by targeting eIF3a. Moreover, miRNA-488 also participates in eIF3a mediated cisplatin resistance in NSCLC cells.

12 January 2019 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
CFchao fang
chao fang
SWSai‐Ying Wang
Sai‐Ying Wang
YLYu‐Ligh Liou
Yu‐Ligh Liou
MCMing‐Hua Chen
Ming‐Hua Chen
WOWen Ouyang
Wen Ouyang
KDKai‐Ming Duan
Kai‐Ming Duan
Background: Paired‐box gene 1 (PAX1), a member of the PAX family, plays a role in pattern formation during embryogenesis, and might be essential for development of the vertebral column.Methods: PAX1 is silenced by methylation in several cancers and is considered a tumor suppressor gene. Our previous studies reported PAX1 as hypermethylated in cervical cancer tissues, thereby suggesting it as a potential screening marker. Recently, an increasing number of studies have confirmed PAX1 methylation as a promising biomarker in cervical cancer based on its excellent discriminatory ability between high‐grade cervical lesions and normal tissues, resulting in a reduced necessity for referral for colposcopy and biopsy. Additionally, PAX1 is also hypermethylated in other tumors, including those associated with epithelial ovarian cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and endometrial carcinoma, and shows relatively good sensitivity and specificity for the detection of these tumors.Results: This review summarizes reports of PAX1 methylation and its promising role in cancer screening, especially that associated with cervical cancer.Conclusion: According to current evidence, combined testing for human papillomavirus and PAX1 methylation analysis represents an efficacious cervical cancer‐screening protocol.

20 September 2017 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
CFchao fang
chao fang
XLXiang‐Ping Li
Xiang‐Ping Li
WGWei‐Jing Gong
Wei‐Jing Gong
NWNa-Yi Yuan Wu
Na-Yi Yuan Wu
JTJie Tang
Jie Tang
ZLZhao-Qian Liu
Zhao-Qian Liu

14 May 2014 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
CFchao fang
chao fang
XRXian Ren
Xian Ren
HZHuan Zhou
Huan Zhou
ZGZhi‐Cheng Gong
Zhi‐Cheng Gong
LSLi Shen
Li Shen
ZLZhao-Qian Liu
Zhao-Qian Liu

1 June 2018 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
CFchao fang
chao fang
XLXiang-Ping Li
Xiang-Ping Li
YCYi-Xin Chen
Yi-Xin Chen
NWNa-Yi Yuan Wu
Na-Yi Yuan Wu
JYJi-Ye Yin
Ji-Ye Yin
ZLZhao-Qian Liu
Zhao-Qian Liu
Background: Platinum-based chemotherapy is widely used as the first-line treatment of lung cancer. MicroRNAs have an important role in lung carcinogenesis and progression. Single-nucleotide polymorphisms (SNPs) in miRNA involved in miRNA biogenesis and structural alteration may affect miRNA expression. In this study, we aimed to investigate the association of functional miRNA variants with the lung cancer susceptibility and platinum-based chemotherapy response. Methods: Nine genetic polymorphisms in miR-605, 146a, 149, 196a-2, 27a, 499, 30c-1, 5197 and let-7a-2 were selected with comprehensive collection strategy and genotyped by MALDI-TOF mass spectrometry in a total of 215 health control and 507 lung cancer patients (386 patients received at least two consecutive cycles of platinum-based chemotherapy). Results: We found that an allele carriers of miR-146a rs2910164 (P=0.022, OR=1.315) and C allele carriers of miR-149 rs71428439 (P=0.042, OR=1.372) performance a high risk of lung cancer. Mir-30c-1 rs928508 (P=0.005, in recessive model) and let-7a-2 rs629367 (P=0.030 and P=0.021, in additive and dominant models, respectively) showed strong relationship with lung cancer risk in age under 57 years. The rs11614913 (miR-196a-2) C allele or rs9280508 (miR-30c-1) G allele carriers shown more sensitive to platinum both in additive (P=0.010, P=0.022, respectively) and dominant models (P=0.001, P=0.018, respectively). Conclusions: These findings suggested that SNPs rs71428439 (miR-149), rs2910164 (miR-146a), rs928508 (mir-30c-1) and rs629367 (let-7a-2) were associated with the lung cancer prevalence, polymorphisms of rs11614913 (miR-196a-2) and rs9280508 (miR-30c-1) significantly influenced the patients’ response to platinum-based chemotherapy, which may serve as potential clinical biomarkers to predict lung cancer risk and platinum-based chemotherapy response.

1 December 2020 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
SLShi-Chao Luo
Shi-Chao Luo
KDKai-Ming Duan
Kai-Ming Duan
CFchao fang
chao fang
DLDan-Yang Li
Dan-Yang Li
SZShan-Shan Zheng
Shan-Shan Zheng
SWsai-ying wang
sai-ying wang
Objective: To investigate the association of genetic polymorphisms of SIRT with postpartum depressive symptoms and analyze the risk factors for postpartum depressive symptoms in women following cesarean section. Methods: A total of 368 Chinese woman undergoing cesarean section were enrolled in this study. A cutoff of ≥ 10 for the Edinburgh Postnatal Depression Scale identified postpartum depressive symptoms. Genotypes of SIRT1, SIRT 2, and SIRT 6 were determined using Sequenom MassArray single-nucleotide polymorphism (SNP) analysis. We analyzed the contribution of genetic factors (SNPs, linkage disequilibrium, and haplotype) to postpartum depressive symptoms and performed logistic regression analysis to identify all potential risk factors for postpartum depressive symptoms and define interactions between genetic and environmental factors. Results: The incidence of postpartum depressive symptoms was 18.7% in this cohort. Univariate analysis suggested that SIRT2 polymorphism at rs2873703 (TT genotype) and rs4801933 ((TT genotype) and SIRT6 polymorphism at rs350846 (CC genotype) and rs107251 (TT genotype) were significantly correlated with the occurrence of postpartum depressive symptoms (p< 0.05). Linkage disequilibrium was identified between SIRT6 polymorphisms rs350846 and rs107251. Incidence of postpartum depressive symptoms in cesarean-section parturients with SIRT2 haplotype CCC was decreased (OR 0.407, 95% CI 0.191– 0.867; p=0.016). SIRT2 polymorphisms rs2873703 and rs4801933 were multiply collinear. Logistic regression analysis showed that SIRT2 polymorphism at rs2873703 (TT genotype) and rs4801933 (TT genotype), domestic violence, stress during pregnancy, and depressive prenatal mood were risk factors for postpartum depressive symptoms (p< 0.05). Conclusion: Pregnant women with SIRT2 genotypes rs2873703 TT and rs4801933 TT and experiencing domestic violence, stress during pregnancy, and prenatal depression are more likely to suffer from postpartum depressive symptoms.